Pycnogenol® for diabetic retinopaty: A review

International Ophthalmology

Volumn 24, Issue 3, 2001, Pages 161-171

  Schönlau, Frank ^a   Rohdewald, Peter ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Diabetes; Diabetic retinopaty; Pycnogenol

Indexed keywords

DOBESILATE CALCIUM; INSULIN; PLACEBO; PYCNOGENOL; RUTOSIDE; SULFONAMIDE; VASODILATOR AGENT; ANTITHROMBOCYTIC AGENT; FLAVONOID; PYCNOGENOLS;

ACCESS TO INFORMATION; CAPILLARY RESISTANCE; CLINICAL TRIAL; CONVALESCENCE; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SCREENING; DRUG TOLERABILITY; FRANCE; GENERAL CONDITION IMPROVEMENT; GERMANY; HEADACHE; HUMAN; ISCHEMIA; KIDNEY DISEASE; NAUSEA; NONHUMAN; OPEN STUDY; OUTCOMES RESEARCH; PINE; RETINA EXUDATE; RETINA HEMORRHAGE; REVIEW; STOMACH DISEASE; TABLET; VASCULAR LESION; VERTIGO; VISUAL ACUITY; VISUAL IMPAIRMENT; ARTICLE; CONTROLLED CLINICAL TRIAL; FLUORESCENCE ANGIOGRAPHY; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

DIABETIC RETINOPATHY; FLAVONOIDS; FLUORESCEIN ANGIOGRAPHY; HUMANS; PINUS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; VISUAL ACUITY;

EID: 0035554244     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021160924583     Document Type: Review

References (39)

1. Shaw JE, Zimmet PZ, McCarty D, De Courten M. Type 2 diabetes worldwide according to the new classification and criteria. Diabetes Care 2000; 23 Suppl 2: B5-10.
2. Taylor HR, Keeffe JE. World blindness: A 21st century perspective. Br J Ophthalmol 2001; 85: 261-6.
3. Hutchinson A, McIntosh A, Peters J, O'Keefe C, Khunti K, Baker R, Booth A. Effectiveness of screening and monitoring tests for diabetic retinopathy - A systematic review. Diabetic Medicine 2000; 17: 495-506.
4. Ferris FL. How effective are treatments for diabetic retinopathy? JAMA 1993; 269: 1290-1.
5. The DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long term complications in insulin dependent diabetes mellitus: The diabetes control and complications trial. New Engl J Med 1993; 329: 977-86.
6. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type II diabetes: (UKPDS 33). Lancet 1998; 352: 837-51.
7. John WG, Lamb EJ. The maillard or browning reaction in diabetes. Eye 1993; 7: 230-7.
8. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia 2001; 44: 129-46.
9. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW et al. Maillard reaction products and their relation to complications in insulin dependent diabetes mellitus. J Clin Invest 1993; 91: 2470-8.
10. Chappey O, Dosquet C, Wautier M-P, Wautier J-L. Advanced glycation end-products, oxidant stress and vascular lesions. Eur J Clin Invest 1997; 27: 97-108.
11. Monnier VM, Glomb M, Elgawish A, Sell DR. The mechanism of collagen cross-linking in diabetes: A puzzle nearing resolution. Diabetes 1996; 45 Suppl 3: 367-72.
12. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol®), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol & Therapeutics 2002; 40: 158-168.
13. Gábor M, Engi E, Sonkodi S. Die Kapillarwandresistenz und ihre Beeinflussung durch wasserlösliche Flavonderivate bei spontan hypertonischen Ratten. Phlebologie 1993; 22: 178-82.
14. Blazsó G, Gábor M, Sibbel R, Rohdewald P. Antiinflammatory and superoxide radical scavenging activities of a procyandin containing extract from the bark of Pinus pinaster Sol. and its fractions. Pharm Pharmacol Lett 1994; 3: 217-20.
15. Blazsó G, Gábor M, Rohdewald P. Antiinflammatory activities of procyanidin-containing extracts from Pinus pinaster Ait after oral and cutaneous application. Pharmazie 1997; 52: 380-2.
16. Gulati OP. Pycnogenol® in venous disorders: A review. Eur Bull Drug Res 1997; 7: 8-13.
17. Bessière E. Étude Clinique de Flavan, Deuxieme Partie: Ophtalmologie. Informations Médicales Laboratoires Millot Paris; 1970.
18. Magnard G, Franck JP, Dorne PA. Intéret du tetrahydroxy flavane diol en ophtalmologie en particulier dans le rétinopathie diabétique. Lyon Med 1970; 4: 1-18.
19. Leydhecker W. Zur Medicamentösen Behandlung der Diabetischen Retinopathie. The Ophthalmology Department of the University Clinic of Würzburg, Germany. Study report, 1986.
20. Spadea L, Balestrazzi E. Treatment of vascular retinopathy with Pycnogenol®. Phytother Res 2001; 15: 219-23.
21. Plantorgan Arzneimittel. Pygnoforton bei diabetischer Retinopathie. Plantorgan Study Report, 1988.
22. Ceriello A. Hyperglycaemia: The bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab 1999; 12: 42-6.
23. Droy-Lefaix MT, Cluzel J, Menerath JM, Bonhomme B, Doly M. Antioxidant effect of a Gingko biloba extract (EGb 761) on the retina. Int J Tissue React 1995; 17: 93-100.
24. Cossins E, Lee R, Packer L. ESR studies of vitamin C regeneration, order of reactivity of natural source phytochemical preparations. Biochem Mol Biol Int 1998; 45: 583-98.
25. Chida M, Suzuki K, Nakanishi-Ueda T, Ueda T, Yasuhara H, Koide R et al. In vitro testing of antioxidants and biochemical end-points in bovine retinal tissue. Ophthalmic Res 1999; 31: 407-15.
26. Trevithick JR, Hirst M, Cukiernik V, Wahlman J, Chartrand M, Dzialoszynski T et al. Pycnogenol antioxidant, and cataract risk reduction experiments. Invest Ophthalmol Vis Sci 2000; 41: 476.
27. Fitzpatrick DF, Bing B, Rohdewald P. Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol 1998; 32: 509-15.
28. Schmetterer L, Findl O, Fasching P, Ferber W, Strenn K, Breiteneder H et al. Nitric oxide and ocular blood flow in patients with IDDM. Diabetes 1997; 46: 653-8.
29. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell S-E, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001; 158: 147-52.
30. Peng Q, Wei Z, Lau BHS. Pycnogenol inhibits tumor necrosis factor-α-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci 2000; 57: 834-41.
31. Cho K-J, Yun C-H, Yoo D-Y, Cho Y-S, Rimbach G, Packer L et al. Effect of bioflavonoid extracted from the bark of Pinus maritima on proinflammatory cytokine interleukin-1 production in lipopolysaccharide-stimulated RAW 264.7. Toxicol Appl Pharmacol 2000; 168: 64-71.
32. Bayetta E, Lau BHS. Pycnogenol inhibits generation of inflammatory mediators in macrophages. Nutrition Res 2000; 20: 249-59.
33. Miyamoto K, Khosrof S, Bursell S-E, Rohan R, Murata T, Clermont A et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 1999; 96: 10836-41.
34. Pütter M, Grotemeyer KHM, Würthwein G, Araghi-Niknam M, Watson RR, Hosseini S et al. Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol. Thromb Res 1999; 95: 155-61.
35. Carr ME. Diabetes mellitus: A hypercoagulable state. J Diabetes Complications 2001; 15: 44-54.
36. Boeri D, Maiello M, Lorenzi M. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 2001; 50: 1432-9.
37. Berthet P, Farine JC, Barras JP. Calcium dobesilate: Pharmacological profile related to its use in diabetic retinopathy. Int J Clin Pract 1999; 53: 631-6.
38. Carlsson K, Patwardhan A, Poullain JC, Gerentes I. Localization of troxerutin in the venous wall measured using laser scanning microscope. J Mal Vascul 1996; 21 (suppl. C): 270-4.
39. Gábor M. The Pharmacology of Benzopyrone Derivatives and Related Compounds. Akadémia Kiadó, Budapest 1986.